{
    "nct_id": "NCT04891640",
    "official_title": "Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis (BACK-OFF JSpA)",
    "inclusion_criteria": "1. Males or females age 8 to 21 years\n2. Juvenile SpA diagnosis (symptom onset before their 16th birthday):\n\n   Pediatric Rheumatology International Trials Organization (PRINTO) revision of the The International League of Associations for Rheumatology (ILAR) criteria enthesitis/spondylitis-related Juvenile idiopathic arthritis (JIA)\n   * Peripheral arthritis and enthesitis, or\n   * Arthritis or enthesitis, plus â‰¥ 3 months of inflammatory back pain and sacroiliitis on imaging, or\n   * Arthritis or enthesitis plus 2 of the following: (1) sacroiliac joint tenderness; (2) inflammatory back pain; (3) presence of Human leukocyte antigen (HLA-B27) ; (4) acute (symptomatic) anterior uveitis; and (5) history of a SpA in a first-degree relative\n3. Currently taking one of the following TNFi therapies (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab) at standard doses and dosing intervals\n4. Have reached a clinically inactive disease state for a minimum of six months, as determined by treating physician\n5. English speaking or Spanish speaking\n6. Interested and willing to de-escalate TNFi therapy\nHealthy volunteers allowed\nMust have minimum age of 8 Years\nMust have maximum age of 21 Years",
    "exclusion_criteria": "1) History of inflammatory bowel disease, history of uveitis that was not adequately controlled with localized ophthalmic treatment or psoriasis that pre-dates the start of TNFi therapy or psoriasis that started after TNFi therapy and has required more than topical therapy for control",
    "miscellaneous_criteria": ""
}